Mol Clin Oncol 2017 Oct 18;7(4):681-686. Epub 2017 Aug 18.
Department of Radiology, University of Tokyo Hospital, Tokyo 113-8655, Japan.
|PDF Download - Full Text Link
( Please be advised that this article is hosted on an external website not affiliated with PubFacts.com)
Radiat Oncol 2016 Jan 19;11. Epub 2016 Jan 19.
Department of Radiology, University of Tokyo Hospital of Bunkyo-ku, Tokyo, Japan.
Background: Standard chemoradiotherapy (CRT) using cisplatin (CDDP) and 5-fluorouracil (5-FU) is an optional treatment for patients with stage II-III esophageal cancer. However, there are some demerits in this regimen because CDDP administration requires a large transfusion volume and 5-FU must be continuously infused over 24 h. Therefore, hospitalization is unavoidable. Read More
Dis Esophagus 2017 02;30(2):1-5
Departments of Radiotherapy, Academic Medical Center Amsterdam , Amsterdam , The Netherlands.
The aim of this study was to determine the outcome of salvage definitive chemoradiation (dCRT) for a locoregional recurrence after any prior curative treatment outside previously irradiated areas. Thirty-nine patients treated between January 2005 and December 2014 were reviewed for locoregional recurrent esophageal cancer outside previously irradiated areas. All patients received salvage treatment with external beam radiotherapy (50. Read More
Dis Esophagus 2014 Feb-Mar;27(2):134-40. Epub 2012 Oct 22.
Division of Thoracic Oncology, West China Hospital, West China School of Clinical Medicine, Sichuan University, Chengdu, China; Division of Radiation Oncology, Zhengzhou University Affiliated Tumor Hospital, Henan Tumor Hospital, Zhengzhou, China.
A consensus treatment strategy for esophageal squamous cell carcinoma (ESCC) patients who recur after definitive radiochemotherapy/radiotherapy has not been established. This study compared the outcomes in ESCC patients who underwent salvage surgery, salvage chemoradiation (CRT) or best supportive care (BSC) for local recurrence. Ninety-five patients with clinical stage I to III ESCC who had completely responded to the initial definitive radiochemotherapy or radiotherapy alone and developed local recurrence were enrolled in this study. Read More
Radiat Oncol 2017 Mar 9;12(1):49. Epub 2017 Mar 9.
Department of Radiation Oncology, Antoine-Lacassagne Cancer Canter, University of Nice Sophia-Antipolis, 33, avenue Valombrose, 06189, Nice Cedex 2, Nice, France.
Background: Optimal management of locally recurrent prostate cancer after definitive radiation therapy is still challenging. With the development of highly accurate radiotherapy devices, prostate salvage re-irradiation might generate lower toxicity rates than classical salvage therapies. We retrospectively evaluated the toxicity and the feasibility of a prostate re-irradiation after definitive radiation therapy failure. Read More